AZD6140

Abstract

Oral antiplatelet therapy with P2Y₁₂ receptor blockers (especially clopidogrel) is the current choice of treatment during acute coronary syndromes and percutaneous interventions. To address the various limitations of thienopyridine therapy (including response variability and non-responsiveness) a novel drug, AZD6140, is under clinical development. AZD6140 is an oral and reversible P2Y₁₂ receptor blocker that does not require hepatic conversion to an active metabolite and produces an overall superior ADP-induced platelet inhibition with less response variability than clopidogrel. It has fast onset and offset actions that may be advantageous in patients who may have to undergo immediate surgery.

Keywords::

• AZD6140
• coronary artery diseases
• P2Y₁₂ receptor blocker
• platelets
• thienopyridines

Disclosure

PA Gurbel has received a research grant from AstraZeneca, Eli Lily, Bayer and Schering-Plough.